Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Blueprint
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Blueprint Medicines is a commercial-stage biopharmaceutical company with two approved kinase inhibitors: avapritinib for PDGFRA exon 18-mutant gastrointestinal stromal tumor and systemic mastocytosis, and pralsetinib for RET-altered cancers (marketed via partners). It has demonstrated strong AYVAKIT/AYVAKYT efficacy in advanced and indolent systemic mastocytosis and continues to generate long-term data in indolent systemic mastocytosis while advancing next-generation KIT inhibitors and additional mast-cell and CDK-targeted programs through early and late clinical development.[1][2][5]
- Therapeutic areas
- HematologyImmunologyDermatologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Roche (global collaboration for pralsetinib/GAVRETO outside certain territories)[1]CStone Pharmaceuticals (development and commercialization rights for avapritinib and pralsetinib in Greater China)[1]
Beyond the preview
Go deeper on Blueprint.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blueprint.